Comparison of incidences of graft-versus-host disease in subgroups of patients treated by bulk dose regimen or escalating-dose regimen
| . | BDR (n = 25) . | EDR (n = 12) . |
|---|---|---|
| Relapse stage | ||
| Cytogenetic | 5 | 4 |
| Hematologic–CP | 16 | 3 |
| Hematologic–AP | 4 | 5 |
| Complete remission | 17 (68%) | 8 (67%) |
| GVHD: | ||
| Acute | ||
| Grade 0 | 8 | 10 |
| Grade 1 | 5 | 1 |
| Grade 2 | 5 | 1 |
| Grades 3-4 | 7 | 0 |
| Chronic | ||
| None/limited | 14 | 11 |
| Extensive | 11 | 1 |
| . | BDR (n = 25) . | EDR (n = 12) . |
|---|---|---|
| Relapse stage | ||
| Cytogenetic | 5 | 4 |
| Hematologic–CP | 16 | 3 |
| Hematologic–AP | 4 | 5 |
| Complete remission | 17 (68%) | 8 (67%) |
| GVHD: | ||
| Acute | ||
| Grade 0 | 8 | 10 |
| Grade 1 | 5 | 1 |
| Grade 2 | 5 | 1 |
| Grades 3-4 | 7 | 0 |
| Chronic | ||
| None/limited | 14 | 11 |
| Extensive | 11 | 1 |
GVHD, graft-versus-host disease; BDR, bulk-dose regimen; EDR, escalating-dose regimen. Lymphocyte doses ranged from 0.4-3.3 × 108/kg.